Back to results
US 11,604,184 B2Granted
Juvenile atopic dermatitis models
AssigneeLaboratoires Expanscience
InventorsCaroline Baudouin, Stephanie Bredif
Life of this patent
Estimating the term…
Abstract
The invention relates to biomarkers in children's skin, in particular in the skin of infants, the expression of which changes when the skin is affected by atopic dermatitis. Such markers are particularly advantageous in that they allow the skin's response to atopic dermatitis to be monitored. The inventors have developed methods for evaluating the in vitro efficacy of formulations in preventing the effects of atopic dermatitis on a child's skin, using a skin model specifically capable of reproducing the characteristics of children's skin.
Claims22
A method for evaluating the in vitro efficacy of a cosmetic active agent, an emollient or a formulation in reducing or treating the effects of atopic dermatitis affecting children's skin, said method comprising determining the efficacy of said cosmetic active agent, emollient or formulation in each of the four tests A, B, C and D, wherein:
- test A comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- c) contacting the reconstructed skin model with a solution comprising poly(deoxyinosinic-deoxycytidylic) acid and interleukin 1 alpha (IL1α);
- d) measuring the expression level of at least one biological marker in the skin;
- and
- e) evaluating the efficacy of said cosmetic active agent, emollient or formulation based on the expression level of the at least one biological marker measured in step d);
- test B comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- c) contacting the reconstructed skin model with a solution comprising at least two Th2 cytokines;
- d) measuring the expression level of at least one biological marker in the skin model;
- and
- e) evaluating the efficacy of said cosmetic active agent, emollient or formulation based on the expression level of the at least one biological marker measured in step d);
- test C comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) growing the reconstructed skin model in the presence of THP-1 monocytes;
- c) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- d) inducing an impairment of the barrier function in the reconstructed skin model;
- e) contacting the reconstructed skin model with at least one pathogenic bacterium;
- f) measuring the expression and/or activation level of at least one biological marker in the skin model;
- and
- g) evaluating the efficacy of said cosmetic active agent, emollient or formulation based on the expression and/or activation level of the at least one biological marker measured in step f);
- and
- test D comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- c) inducing an impairment of the barrier function in the reconstructed skin model;
- d) contacting the reconstructed skin model with at least one pathogenic bacterium;
- e) measuring the expression and/or activation level of at least one biological marker in the skin model;
- and
- f) evaluating the efficacy of said cosmetic active agent, emollient or formulation based on the expression and/or activation level of the least one biological marker measured in step e).
29 more elements
A method for evaluating the tolerance of a cosmetic active agent, an emollient or a formulation by children's atopic skin, said method comprising determining the tolerance of said cosmetic active agent, emollient or formulation by said children's atopic skin in each of the four tests A, B, C and D, wherein:
- test A comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- c) contacting the reconstructed skin model with a solution comprising poly(deoxyinosinic-deoxycytidylic) acid and interleukin 1 alpha (IL1α);
- d) measuring the expression level of at least one biological marker in the skin model;
- and
- e) determining whether said cosmetic active agent, emollient or formulation is well tolerated by children's atopic skin based on the expression level of the least one biological marker measured step d);
- test B comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) bringing said cosmetic active agent, emollient or formulation into contact with the reconstructed skin model;
- c) bringing the reconstructed skin model into contact with a solution comprising at least two Th2 cytokines;
- d) measuring the expression level of at least one biological marker in the skin model;
- and
- e) determining whether said cosmetic active agent, emollient or formulation is well tolerated by children's atopic skin based on the expression level of the least one biological marker measured step d);
- test C comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) growing the reconstructed skin model in the presence of THP-1 monocytes;
- c) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- d) inducing an impairment of the barrier function in the reconstructed skin model;
- e) contacting the reconstructed skin model with at least one pathogenic bacterium;
- f) measuring the expression and/or activation level of at least one biological marker in the skin model;
- and
- g) determining whether said cosmetic active agent, emollient or formulation is well tolerated by children's atopic skin based on the expression and/or activation level of the least one biological marker measured step f);
- and
- test D comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- c) inducing an impairment of the barrier function in the reconstructed skin model;
- d) contacting the reconstructed skin model with at least one pathogenic bacterium;
- e) measuring the expression and/or activation level of at least one biological marker in the skin model;
- and
- f) determining whether said cosmetic active agent, emollient or formulation is well tolerated by children's atopic skin based on the expression and/or activation level of the least one biological marker measured step e).
29 more elements
A method for identifying a cosmetic active agent, an emollient or a formulation for reducing the effects of atopic dermatitis affecting children's skin, said method comprising determining the efficacy of said cosmetic active agent, emollient or formulation in reducing the effects of atopic dermatitis of children's skin in each of the four tests A, B, C and D, wherein:
- test A comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) contacting the reconstructed skin model with a solution comprising poly(deoxyinosinic-deoxycytidylic) acid and interleukin 1 alpha (IL1α);
- c) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- d) measuring the expression level of at least one biological marker in the skin model;
- and
- e) determining whether said candidate cosmetic active agent, emollient or formulation is a cosmetic active agent, emollient or formulation for reducing the effects of atopic dermatitis on children's skin based on the expression level of the least one biological marker measured step d);
- test B comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) contacting the reconstructed skin model with a solution comprising at least two Th2 cytokines;
- c) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- d) measuring the expression level of at least one biological marker in the skin model;
- and
- e) determining whether said candidate cosmetic active agent, emollient or formulation is a cosmetic active agent, emollient or formulation for reducing the effects of atopic dermatitis on children's skin based on the expression level of the least one biological marker measured step d);
- test C comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) growing the reconstructed skin model in the presence of THP-1 monocytes;
- c) inducing an impairment of the barrier function in the reconstructed skin model;
- d) contacting the reconstructed skin model with at least one pathogenic bacterium;
- e) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- f) measuring the expression and/or activation level of at least one biological marker in the skin model;
- and
- g) determining whether said candidate cosmetic active agent, emollient or formulation is a cosmetic active agent, emollient or formulation for reducing the effects of atopic dermatitis on children's skin based on the expression and/or activation level of the least one biological marker measured step f);
- and
- test D comprises the following steps:
- a) obtaining a reconstructed skin model from a skin sample from a child;
- b) inducing an impairment of the barrier function in the reconstructed skin model;
- c) contacting the reconstructed skin model with at least one pathogenic bacterium;
- d) contacting said cosmetic active agent, emollient or formulation with the reconstructed skin model;
- e) measuring the expression and/or activation level of at least one biological marker in the skin model;
- and
- f) determining whether said candidate cosmetic active agent, emollient or formulation is a cosmetic active agent, emollient or formulation for reducing the effects of atopic dermatitis on children's skin based on the expression and/or activation level of the least one biological marker measured step e).
29 more elements
Dependencies are inferred from the claim text.